Cited by 871Sepsis Diagnosis and TreatmentAutoimmune and Inflammatory Disorders ResearchInflammation biomarkers and pathways

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*

Open access

Shakoory, Bita, Carcillo, Joseph A., Chatham, W. Winn, Amdur, Richard L., Zhao, Huaqing, Dinarello, Charles A., Cron, Randall Q., Opal, Steven M.·2016·Critical Care Medicine

DOI 10.1097/ccm.0000000000001402PMC PMC5378312

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To determine the efficacy of anakinra (recombinant interleukin-1 receptor antagonist) in improving 28-day survival in sepsis patients with features of macrophage activation syndrome. Despite equivocal results in sepsis trials, anakinra is effective in treating macrophage activation syndrome, a similar entity with fever, disseminated intravascular coagulation, hepatobiliary dysfunction, cytopenias, and hyperferritinemia. Hence, sepsis patients with macrophage activation syndrome features may benefit from interleukin-1 receptor blockade. DESIGN: Reanalysis of deidentified data from the phase III randomized interleukin-1 receptor antagonist trial in severe sepsis. SETTING: Multicenter study recruiting through 91 centers from 11 countries in Europe and North America. PATIENTS: Sepsis patients with multiorgan dysfunction syndrome and/or shock (original study) were regrouped based on the presence or the absence of concurrent hepatobiliary dysfunction and disseminated intravascular coagulation as features of macrophage activation syndrome. The non-hepatobiliary dysfunction/disseminated intravascular coagulation group included patients with only hepatobiliary dysfunction, only disseminated intravascular coagulation, or neither. INTERVENTION: Treatment with anakinra or placebo. MEASUREMENTS AND MAIN RESULTS: Main outcome was 28-day mortality. Descriptive and comparative statistics were performed. Data were available for 763 adults from the original study cohort, randomized to receive either anakinra or placebo. Concurrent hepatobiliary dysfunction/disseminated intravascular coagulation was noted in 43 patients (5.6% of total; 18-75 years old; 47% women). The 28-day survival was similar in both anakinra and placebo-treated non-hepatobiliary dysfunction/disseminated intravascular coagulation patients (71.4% vs 70.8%; p = 0.88). Treatment with anakinra was associated with significant improvement in the 28-day survival rate in hepatobiliary dysfunction/disseminated intravascular coagulation patients (65.4% anakinra vs 35.3% placebo), with hazard ratio for death 0.28 (0.11-0.71; p = 0.0071) for the treatment group in Cox regression. CONCLUSIONS: In this subgroup analysis, interleukin-1 receptor blockade was associated with significant improvement in survival of patients with sepsis and concurrent hepatobiliary dysfunction/disseminated intravascular coagulation. A prospective randomized trial using features of macrophage activation syndrome for mortality risk stratification should be undertaken to confirm the role of interleukin-1 blockage.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/ccm.0000000000001402

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E. H., Angus, D. C., Cook, D., Cohen, J., Opal, S. M., Vincent, J., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,976
Self-citation
The Pathophysiology and Treatment of Sepsis
Hotchkiss, R. S., & Karl, I. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021333 · Cited by 4,132
An Expanded Definition of the Adult Respiratory Distress Syndrome
Murray, J. F., Matthay, M. A., Luce, J. M., & Flick, M. R. (1988) · American Review of Respiratory Disease · doi:10.1164/ajrccm/138.3.720 · Cited by 2,641
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Self-citation
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,810
Self-citation
Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome
Fardet, L., Galicier, L., Lambotte, O., Marzac, C., Aumont, C., Chahwan, D., Coppo, P., & Hejblum, G. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38690 · Cited by 1,508
Interleukin-1 and the Pathogenesis of the Acute-Phase Response
Epstein, F. H., & Dinarello, C. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411293112205 · Cited by 1,151
Self-citation
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis
Opal, S. M., Fisher, C. J., Dhainaut, J.-F., Vincent, J., Brase, R., Lowry, S. F., SADOFF, J. C., Slotman, G. J., Levy, H. A., BALK, R. A., et al. (1997) · Critical Care Medicine · doi:10.1097/00003246-199707000-00010 · Cited by 882
Self-citation
Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial
Fisher, C. J. (1994) · JAMA · doi:10.1001/jama.1994.03510470040032 · Cited by 790
Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis
Allen, C. E., Yu, X., Kozinetz, C. A., & McClain, K. L. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21423 · Cited by 637

Show all 48 references

Research works printed but not linked: 4

Emmenegger, 2005, Swiss Med Wkly, 135, 299
Behrens, 2007, J Rheumatol, 34, 1133
Behrens, 2006, J Rheumatol, 33, 2081
Marti-Carvajal, 2012, Cochrane Database Syst Rev, 12, CD004388

Sorted by citations

Items 101–200 of 871

The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)
Shakoory, B., Geerlinks, A. V., Wilejto, M., Kernan, K. F., Hines, M., Romano, M., Piskin, D., Ravelli, A., Sinha, R. R., Aletaha, D., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224123 · Cited by 162
Self-citation
Acute respiratory distress syndrome
Wick, K. D., Ware, L. B., & Matthay, M. A. (2024) · BMJ · doi:10.1136/bmj-2023-076612 · Cited by 185
Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19
Ramarao, P., Joshi, G., & Jagadeesh, G. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109721 · Cited by 160
Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial
Leventogiannis, K., Kyriazopoulou, E., Antonakos, N., Kotsaki, A., Tsangaris, I., Markopoulou, D., Grondman, I., Rovina, N., Theodorou, V., Antoniadou, E., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100817 · Cited by 155
T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis
Chaturvedi, V., Marsh, R. A., Zoref‐Lorenz, A., Owsley, E., Chaturvedi, V., Nguyen, T. C., Goldman, J. R., Henry, M. M., Greenberg, J. N., Ladisch, S., et al. (2020) · Blood · doi:10.1182/blood.2020009499 · Cited by 145
Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults
Hines, M., Greenwood, T. V. B., Beutel, G., Beutel, K., Hays, J. A., Horne, A., Janka, G., Jordan, M. B., van Laar, J. A. M., Lachmann, G., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005361 · Cited by 144
Self-citation
Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic
Soy, M., Atagündüz, P., Atagündüz, I., & Sucak, G. T. (2020) · Rheumatology International · doi:10.1007/s00296-020-04636-y · Cited by 143
Sepsis-associated brain injury: underlying mechanisms and potential therapeutic strategies for acute and long-term cognitive impairments
Sekino, N., Selim, M. H., & Shehadah, A. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02464-4 · Cited by 146
Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis
Wohlfarth, P., Agis, H., Gualdoni, G. A., Weber, J., Staudinger, T., Schellongowski, P., & Robak, O. (2017) · Journal of Intensive Care Medicine · doi:10.1177/0885066617711386 · Cited by 140
Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications
Pelaia, C., Tinello, C., Vatrella, A., Sarro, G. D., & Pelaia, G. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620933508 · Cited by 136
Intensive Care Unit-Acquired Weakness: Not Just Another Muscle Atrophying Condition
Lad, H., Saumur, T. M., Herridge, M. S., dos Santos, C. C., Mathur, S., Batt, J. A. E., & Gilbert, P. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217840 · Cited by 150
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)
Wehrli, M., Gallagher, K., Chen, Y., Leick, M. B., McAfee, S. L., El-Jawahri, A. R., DeFilipp, Z. M., Horick, N., O’Donnell, P. V., Spitzer, T. R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003847 · Cited by 142
Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies
Bonaventura, A., Vecchié, A., Wang, T. S., Lee, E., Cremer, P. C., Carey, B. C., Rajendram, P., Hudock, K. M., Korbee, L. L., Tassell, B. W. V., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01625 · Cited by 137
CNS implications of COVID-19: a comprehensive review
Nagu, P., Parashar, A., Behl, T., & Mehta, V. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0070 · Cited by 134
Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities
Mehta, P., Porter, J. C., Manson, J. J., Isaacs, J. D., Openshaw, P., McInnes, I. B., Summers, C., & Chambers, R. C. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30267-8 · Cited by 131
Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease
Pontali, E., Volpi, S., Antonucci, G., Castellaneta, M., Buzzi, D., Tricerri, F., Angelelli, A., Caorsi, R., Feasi, M., Calautti, F., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.002 · Cited by 131
Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity
Diamanti, A. P., Rosado, M. M., Pioli, C., Sesti, G., & Laganà, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093330 · Cited by 129
Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents
Khadke, S., Ahmed, N., Ahmed, N., Ratts, R., Raju, S., Gallogly, M. M., Lima, M. J. G. D., & Sohail, M. R. (2020) · Virology Journal · doi:10.1186/s12985-020-01415-w · Cited by 127
Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study
the RCI-COVID-19 Study Group, Kooistra, E. J., Waalders, N. J. B., Grondman, I., Janssen, N. A. F., de Nooijer, A. H., Netea, M. G., van de Veerdonk, F. L., Ewalds, E., van der Hoeven, J. G., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03364-w · Cited by 119
COVID-19 infection: the China and Italy perspectives
Chen, J., Lu, H., Melino, G., Boccia, S., Piacentini, M., Ricciardi, W., Wang, Y., Shi, Y., & Zhu, T. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2603-0 · Cited by 130
Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders
Arnold, D. D., Yalamanoglu, A., & Boyman, O. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.888392 · Cited by 138
From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations for Developing Precision Medicine in the ICU
Gordon, A. C., Alipanah, N., Bos, L. D. J., Dianti, J., Diaz, J. V., Finfer, S. R., Fujii, T., Giamarellos‐Bourboulis, E. J., Goligher, E. C., Gong, M. N., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202311-2086so · Cited by 130
Cytokine Storm in COVID-19: “When You Come Out of the Storm, You Won’t Be the Same Person Who Walked in”
Castelli, V., Cimini, A., & Ferri, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02132 · Cited by 129
The role of Interleukin 6 inhibitors in therapy of severe COVID-19
Nasonov, E. L., & MIu, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110698 · Cited by 126
Control of Cell Death in Health and Disease
Kayagaki, N., Webster, J. D., & Newton, K. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051022-014433 · Cited by 127
The Rheumatologist’s Role in COVID-19
Cron, R. Q., & Chatham, W. W. (2020) · The Journal of Rheumatology · doi:10.3899/jrheum.200334 · Cited by 123
Self-citation
Oral nano‐curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease ‐19 patients: An open label nonrandomized clinical trial
Saber‐Moghaddam, N., Salari, S., Hejazi, S., Amini, M., Taherzadeh, Z., Eslami, S., Rezayat, S. M., Jaafari, M. R., & Elyasi, S. (2021) · Phytotherapy Research · doi:10.1002/ptr.7004 · Cited by 124
Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19
Saha, R. P., Sharma, A. R., Singh, M. K., Samanta, S., Bhakta, S., Mandal, S., Bhattacharya, M., Lee, S. S., & Chakraborty, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01258 · Cited by 118
Targeting the host response in sepsis: current approaches and future evidence
Bode, C., Weis, S., Sauer, A., Wendel‐Garcia, P. D., & David, S. (2023) · Critical Care · doi:10.1186/s13054-023-04762-6 · Cited by 127
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Zhou, Y., Xie, Y., Tang, L., Pu, D., Zhu, Y., Liu, J., & Ma, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00733-x · Cited by 116
The Metabolic Basis of Immune Dysfunction Following Sepsis and Trauma
McBride, M. A., Owen, A. M., Stothers, C. L., Hernandez, A., Luan, L., Burelbach, K. R., Patil, T. K., Bohannon, J. K., Sherwood, E. R., & Patil, N. K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01043 · Cited by 120
Pathophysiology of Pediatric Multiple Organ Dysfunction Syndrome
Carcillo, J. A., Podd, B. S., Aneja, R. K., Weiss, S. L., Hall, M. W., Cornell, T. T., Shanley, T. P., Doughty, L., & Nguyen, T. C. (2017) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000001052 · Cited by 110
Self-citation
Understanding, assessing and treating immune, endothelial and haemostasis dysfunctions in bacterial sepsis
Girardis, M., David, S., Ferrer, R., Helms, J., Juffermans, N. P., Martín‐Loeches, I., Póvoa, P. M. S. R., Russell, L., Shankar‐Hari, M., Iba, T., et al. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07586-2 · Cited by 120
Cancer and COVID-19: Unmasking their ties
Addeo, A., & Friedlaender, A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102041 · Cited by 118
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications
Iannaccone, G., Scacciavillani, R., Buono, M. G. D., Camilli, M., Ronco, C., Lavie, C. J., Abbate, A., Crea, F., Massetti, M., & Aspromonte, N. (2020) · Cardiorenal Medicine · doi:10.1159/000509483 · Cited by 112
Precision Immunotherapy to Improve Sepsis Outcomes
Giamarellos‐Bourboulis, E. J., Kotsaki, A., Kotsamidi, I., Efthymiou, A., Koutsoukou, V., Ehler, J., Paridou, A., Frantzeskaki, F. G., Müller, M. C. A., Pickkers, P., et al. (2025) · JAMA · doi:10.1001/jama.2025.24175 · Cited by 122
Immune dysregulation and system pathology in COVID-19
Jamal, M., Bangash, H. I., Habiba, M., Lei, Y., Xie, T., Sun, J., Wei, Z., Hong, Z., Shao, L., & Zhang, Q. (2021) · Virulence · doi:10.1080/21505594.2021.1898790 · Cited by 121
Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome
Halyabar, O., Chang, M. H., Schoettler, M. L., Schwartz, M. A., Barış, H. E., Benson, L. A., Biggs, C. M., Gorman, M., Lehmann, L., Lo, M. S., et al. (2019) · Pediatric Rheumatology · doi:10.1186/s12969-019-0309-6 · Cited by 108
Out of Control: The Role of the Ubiquitin Proteasome System in Skeletal Muscle during Inflammation
Haberecht-Müller, S., Krüger, E., & Fielitz, J. (2021) · Biomolecules · doi:10.3390/biom11091327 · Cited by 108
Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms
Wu, Y., Sun, X., Kang, K., Yang, Y., Li, H., Zhao, A., & Niu, T. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01621-x · Cited by 115
Blocking IL-1 to prevent respiratory failure in COVID-19
van de Veerdonk, F. L., & Netea, M. G. (2020) · Critical Care · doi:10.1186/s13054-020-03166-0 · Cited by 106
Persistent inflammation, immunosuppression, and catabolism syndrome (PICS): a review of definitions, potential therapies, and research priorities
Chadda, K. R., & Puthucheary, Z. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2023.11.052 · Cited by 116
Sepsis-induced immunosuppression: mechanisms, biomarkers and immunotherapy
Gao, X., Cai, S., Li, X., & Wu, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1577105 · Cited by 120
Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration*
Meyer, N. J., Reilly, J. P., Anderson, B. J., Palakshappa, J. A., Jones, T. K., Dunn, T. G., Shashaty, M. G. S., Feng, R., Christie, J. D., & Opal, S. M. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002749 · Cited by 102
Self-citation
Subphenotypes in acute kidney injury: a narrative review
Vaara, S. T., Bhatraju, P. K., Stanski, N. L., McMahon, B. A., Liu, K. D., Joannidis, M., & Bagshaw, S. M. (2022) · Critical Care · doi:10.1186/s13054-022-04121-x · Cited by 106
Postoperative Ileus: Pathophysiology, Current Therapeutic Approaches
Stakenborg, N., Gomez‐Pinilla, P. J., & Boeckxstaens, G. E. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_108 · Cited by 104
Immunopathology of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and Immune-Therapeutic Implications
Allegra, A., Gioacchino, M. D., Tonacci, A., Musolino, C., & Gangemi, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134782 · Cited by 98
Defining immunological dysfunction in sepsis: A requisite tool for precision medicine
Bermejo-Martín, J. F., Andaluz‐Ojeda, D., Almansa, R., Gandía, F., Gomez-Herreras, J. I., Gómez‐Sánchez, E., Heredia‐Rodríguez, M., Bouza, J. M. E., Kelvin, D. J., & Tamayo, E. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.01.010 · Cited by 99
Pathogenesis and Treatment of Cytokine Storm Induced by Infectious Diseases
Tang, X., Ji, T.-T., Dong, J.-R., Feng, H., Chen, F.-Q., Chen, X., Zhao, H., Chen, D., & Ma, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313009 · Cited by 108
Self-citation
A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis
Zhang, M., Bracaglia, C., Prencipe, G., Bemrich-Stolz, C. J., Beukelman, T., Dimmitt, R. A., Chatham, W. W., Zhang, K., Li, H., Walter, M. R., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501284 · Cited by 99
Self-citation
Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm
Ruscitti, P., Berardicurti, O., Benedetto, P. D., Cipriani, P., Iagnocco, A., Shoenfeld, Y., & Giacomelli, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01130 · Cited by 100
Three Hypothetical Inflammation Pathobiology Phenotypes and Pediatric Sepsis-Induced Multiple Organ Failure Outcome*
Carcillo, J. A., Halstead, E. S., Hall, M. W., Nguyen, T. C., Reeder, R., Aneja, R. K., Shakoory, B., & Simon, D. W. (2017) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000001122 · Cited by 97
Self-citation
Sepsis and Coronavirus Disease 2019: Common Features and Anti-Inflammatory Therapeutic Approaches
Beltrán-García, J., Osca-Verdegal, R., Pallardó, F. V., Ferreres, J., Rodríguez, M. D. P., Mulet, S., Ferrando-Sánchez, C., Carbonell, N., & García‐Giménez, J. L. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004625 · Cited by 99
The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?
Morris, G., Bortolasci, C. C., Puri, B. K., Marx, W., O'Neil, A. E., Athan, E., Walder, K. R., Berk, M., OLIVE, L. S., Carvalho, A. F., et al. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155593 · Cited by 101
NF-κB Signaling and Inflammation—Drug Repurposing to Treat Inflammatory Disorders?
Roberti, A., Chaffey, L., & Greaves, D. R. (2022) · Biology · doi:10.3390/biology11030372 · Cited by 107
A Multicenter Network Assessment of Three Inflammation Phenotypes in Pediatric Sepsis-Induced Multiple Organ Failure
Carcillo, J. A., Berg, R. A., WESSEL, D. L., Pollack, M. M., Meert, K. L., Hall, M. W., Newth, C. J. L., Lin, J. C., Doctor, A., Shanley, T., et al. (2019) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000002105 · Cited by 95
Self-citation
Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options
Nazerian, Y., Ghasemi, M., Yassaghi, Y., Nazerian, A., & Hashemi, S. M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109428 · Cited by 96
Emerging pharmacological therapies for ARDS: COVID-19 and beyond
Horie, S., McNicholas, B., Rezoagli, E., Pham, T. O., Curley, G., McAuley, D. F., O’Kane, C. M., Nichol, A., dos Santos, C. C., Rocco, P. R. M., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06141-z · Cited by 100
Advances in Immune Monitoring Approaches for Sepsis-Induced Immunosuppression
Yao, R.-Q., Ren, C., Zheng, L., Xia, Z., & Yao, Y.-M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.891024 · Cited by 96
The genetics of macrophage activation syndrome
Schulert, G. S., & Cron, R. Q. (2020) · Genes & Immunity · doi:10.1038/s41435-020-0098-4 · Cited by 91
Self-citation
A Systemic Inflammation Mortality Risk Assessment Contingency Table for Severe Sepsis*
Carcillo, J. A., Sward, K. A., Halstead, E. S., Telford, R., Jimenez-Bacardi, A., Shakoory, B., Simon, D. W., & Hall, M. W. (2016) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000001029 · Cited by 91
Self-citation
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response
Arnaldez, F. I., O'Day, S. J., Drake, C. G., Fox, B. A., Fu, B., Urba, W. J., Montesarchio, V., Weber, J. S., Wei, H., Wigginton, J. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000930 · Cited by 92
Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.
Pasin, L., Cavalli, G., Navalesi, P., Sella, N., Landoni, G., Yavorovskiy, A. G., Likhvantsev, V. V., Zangrillo, A., Dagna, L., & Monti, G. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.01.016 · Cited by 92
Network pharmacology analysis of the therapeutic mechanisms of the traditional Chinese herbal formula Lian Hua Qing Wen in Corona virus disease 2019 (COVID-19), gives fundamental support to the clinical use of LHQW
Zheng, S., Baak, J. P. A., Li, S., Xiao, W., Ren, H. G., Yang, H., Gan, Y., & Wen, C. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153336 · Cited by 88
Traumatic inflammatory response: pathophysiological role and clinical value of cytokines
Li, R., Ye, J. J., Gan, L., Zhang, M., Sun, D., Li, Y., Wang, T., & Chang, P. (2023) · European Journal of Trauma and Emergency Surgery · doi:10.1007/s00068-023-02388-5 · Cited by 87
Glucocorticoid resistance as a major drive in sepsis pathology
Dendoncker, K., & Libert, C. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.04.002 · Cited by 85
Part I: Minimum Quality Threshold in Preclinical Sepsis Studies (MQTiPSS) for Study Design and Humane Modeling Endpoints
Zingarelli, B., Coopersmith, C. M., Drechsler, S., Efron, P. A., Marshall, J. C., Moldawer, L. L., Wiersinga, W. J., Xiao, X., Osuchowski, M. F., & Thiemermann, C. (2018) · Shock · doi:10.1097/shk.0000000000001243 · Cited by 91
A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome
Khiali, S., Khani, E., & Entezari‐Maleki, T. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1693 · Cited by 87
Oxidative Stress‐Related Mechanisms in SARS‐CoV‐2 Infections
Wieczfińska, J., Kleniewska, P., & Pawliczak, R. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5589089 · Cited by 91
Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?
Rossi, F., Tortora, C., Argenziano, M., Paola, A. D., & Punzo, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113809 · Cited by 83
Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases?
Opoka‐Winiarska, V., Grywalska, E., & Roliński, J. (2020) · BMC Medicine · doi:10.1186/s12916-020-01682-y · Cited by 84
Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm
Narain, S., Stefanov, D. G., Chau, A. S., Weber, A. G., Marder, G. S., Kaplan, B. M., Malhotra, P., Bloom, O., Liu, A., LESSER, M. L., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.09.275 · Cited by 84
SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment
Prete, M., Favoino, E., Catacchio, G., Racanelli, V., & Perosa, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093377 · Cited by 82
Multisystem inflammatory syndrome associated with COVID-19 from the pediatric emergency physician's point of view
Simon, H., Sakano, T. M. S., Rodrigues, R. M., Eisencraft, A. P., Carvalho, V. E. D. L., Schvartsman, C., & Reis, A. G. (2020) · Jornal de Pediatria · doi:10.1016/j.jped.2020.08.004 · Cited by 82
Lipid and Lipoprotein Dysregulation in Sepsis: Clinical and Mechanistic Insights into Chronic Critical Illness
Barker, G., Leeuwenburgh, C., Brusko, T. M., Moldawer, L. L., Reddy, S. T., & Guirgis, F. W. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081693 · Cited by 83
Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation
Böhm, M., Frey, N., Giannitsis, E., Sliwa, K. S., & Zeiher, A. M. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01656-3 · Cited by 80
Immune response mechanisms in acute and chronic pancreatitis: strategies for therapeutic intervention
Glaubitz, J., Asgarbeik, S., Lange, R., Mazloum, H., Elsheikh, H., Weiß, F. U., & Sendler, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1279539 · Cited by 81
Convergent pathways of the hyperferritinemic syndromes
Schulert, G. S., & Canna, S. (2018) · International Immunology · doi:10.1093/intimm/dxy012 · Cited by 77
Cytokines and COVID-19: friends or foes?
Rokni, M., Hamblin, M. R., & Rezaei, N. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1799669 · Cited by 77
Downregulation of lncRNA NEAT1 Ameliorates LPS-Induced Inflammatory Responses by Promoting Macrophage M2 Polarization via miR-125a-5p/TRAF6/TAK1 Axis
Wang, W., & Guo, Z. (2020) · Inflammation · doi:10.1007/s10753-020-01231-y · Cited by 77
Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality
Imazio, M., Brucato, A. L., Lazaros, G. A., Andreis, A., Scarsi, M., Klein, A. L., Ferrari, G. M. D., & Adler, Y. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001059 · Cited by 78
Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia
Pontali, E., Volpi, S., Signori, A., Antonucci, G., Castellaneta, M., Buzzi, D., Montale, A., Bustaffa, M., Angelelli, A., Caorsi, R., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.01.024 · Cited by 76
Pediatric Sepsis Diagnosis, Management, and Sub-phenotypes
Weiss, S. L., & Fitzgerald, J. C. (2023) · PEDIATRICS · doi:10.1542/peds.2023-062967 · Cited by 88
Diagnostic and management of life-threatening Adult-Onset Still Disease: a French nationwide multicenter study and systematic literature review
Néel, A., Wahbi, A., Tessoulin, B., Boileau, J., Carpentier, D., Decaux, O., Fardet, L., Géri, G., Godmer, P., Goujard, C., et al. (2018) · Critical Care · doi:10.1186/s13054-018-2012-2 · Cited by 76
Hemophagocytic Lymphohistiocytosis: Potentially Underdiagnosed in Intensive Care Units
Lachmann, G., Spies, C., Schenk, T., Brunkhorst, F. M., Balzer, F., & Rosée, P. G. L. (2017) · Shock · doi:10.1097/shk.0000000000001048 · Cited by 75
Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review
Roshanravan, N., Seif, F., Ostadrahimi, A., Pouraghaei, M., & Ghaffari, S. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.06.012 · Cited by 77
SARS, MERS and COVID-19: clinical manifestations and organ-system complications: a mini review
Harb, J. G., Noureldine, H. A., Chedid, G., Eldine, M. N., Abdallah, D. A., Chedid, N. F., & Nour‐Eldine, W. (2020) · Pathogens and Disease · doi:10.1093/femspd/ftaa033 · Cited by 76
Epidemiology, characteristics, and outcomes of adult haemophagocytic lymphohistiocytosis in the USA, 2006–19: a national, retrospective cohort study
Abdelhay, A., Mahmoud, A. A., Ali, O. A., Hashem, A. M., Orakzai, A., & Jamshed, S. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102143 · Cited by 74
Derivation and Validation of Novel Phenotypes of Multiple Organ Dysfunction Syndrome in Critically Ill Children
Sanchez-Pinto, L. N., Stroup, E. K., Pendergrast, T. R., Pinto, N. P., & Luo, Y. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.9271 · Cited by 74
The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm
Chau, A. S., Weber, A. G., Maria, N. I., Narain, S., Liu, A., Hajizadeh, N., Malhotra, P., Bloom, O., Marder, G. S., & Kaplan, B. M. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41526 · Cited by 75
Highways to hell: Mechanism-based management of cytokine storm syndromes
Canna, S., & Cron, R. Q. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.09.016 · Cited by 74
Self-citation
A Personalized Diagnostic and Treatment Approach for Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Adults
Kumar, B., Aleem, S., Saleh, H., Petts, J., & Ballas, Z. K. (2017) · Journal of Clinical Immunology · doi:10.1007/s10875-017-0439-x · Cited by 70
Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis
Tlayjeh, H., Mhish, O. H., Enani, M. A., Alruwaili, A., Tleyjeh, R., Thalib, L., Hassett, L. C., Arabi, Y. M., Kashour, T. S., & Tleyjeh, I. M. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.09.008 · Cited by 74
Inflammatory Mechanisms in COVID-19 and Atherosclerosis: Current Pharmaceutical Perspectives
Sagris, Μ., Theofilis, P., Antonopoulos, A. S., Tsioufis, C. P., Oikonomou, E. K., Antoniades, C. A., Crea, F., Kaski, J. C., & Tousoulis, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126607 · Cited by 71
Cutaneous sıde‐effects of the potential COVID‐19 drugs
Türsen, Ü., Türsen, B., & Lotti, T. (2020) · Dermatologic Therapy · doi:10.1111/dth.13476 · Cited by 69
Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure
Cavalli, G., Foppoli, M., Cabrini, L., Dinarello, C. A., Tresoldi, M., & Dagna, L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00131 · Cited by 70
Self-citation
Towards personalized medicine: a scoping review of immunotherapy in sepsis
Slim, M. A., van Mourik, N., Bakkerus, L., Fuller, K., Acharya, L. S., Giannidis, T., Dionne, J. C., Oczkowski, S. J. W., Netea, M. G., Pickkers, P., et al. (2024) · Critical Care · doi:10.1186/s13054-024-04964-6 · Cited by 93
COVID-19 and lung cancer: risks, mechanisms and treatment interactions
Addeo, A., Obéid, M., & Friedlaender, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000892 · Cited by 71
Possible Pathogenesis and Prevention of Long COVID: SARS-CoV-2-Induced Mitochondrial Disorder
Chen, T., Chang, C.-J., & Hung, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098034 · Cited by 73
COVID‐19 and immunological regulations – from basic and translational aspects to clinical implications
Schön, M. P., Berking, C., Biedermann, T., Buhl, T., Erpenbeck, L., Eyerich, K., Eyerich, S., Ghoreschi, K., Goebeler, M., Ludwig, R. J., et al. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14169 · Cited by 67

Authors: Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M.
Affiliations: George Washington University (US)
University of Pittsburgh Medical Center (US)
University of Alabama at Birmingham (US)
Temple University (US)
University of Colorado Anschutz (US)
Brown University (US)
ORCID: Shakoory, Bita
Carcillo, Joseph A.
Chatham, W. Winn
Amdur, Richard L.
Zhao, Huaqing
Dinarello, Charles A.
Venue: Critical Care Medicine
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2016-02
Volume: 44
Issue: 2
Pages: 275-281
ISSN: 0090-3493 (ISSN-L)
DOI: 10.1097/ccm.0000000000001402
PMC: PMC5378312
OpenAlex: W2177407033
Cited by: 867
References: 48
Citations by year: 2026: 66 · 2025: 64 · 2024: 68 · 2023: 76 · 2022: 87 · 2021: 141 · 2020: 226 · 2019: 43 · 2018: 36 · 2017: 42 · 2016: 15
FWCI: 24.58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Critical Care Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of General Medical Sciences (R01GM108618)
Topics: Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Keywords: sepsis, anakinra, interleukin-1 receptor antagonist, interleukin-1 blockade, 28-day mortality, hepatobiliary dysfunction, disseminated intravascular coagulation, multiple organ failure, septic shock, subgroup analysis, hyperferritinemia, cytokine storm
MeSH terms: Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Biliary Tract Diseases, Disseminated Intravascular Coagulation, Double-Blind Method, Female, Humans, Liver Diseases, Male, Middle Aged, Multiple Organ Failure, Respiratory Distress Syndrome, Sex Factors, Shock, Septic, Receptors, Interleukin-1, Sepsis, APACHE, Interleukin 1 Receptor Antagonist Protein, Macrophage Activation Syndrome, Young Adult, Acute Kidney Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks